Show simple item record

dc.contributor.authorBliss, J
dc.contributor.authorKernaghan, S
dc.contributor.authorFribbens, C
dc.contributor.authorStevenson, L
dc.contributor.authorMorden, J
dc.contributor.authorSnowdon, C
dc.contributor.authorMacpherson, I
dc.contributor.authorWardley, Andrew M
dc.contributor.authorRoylance, R
dc.contributor.authorBaird, R
dc.date.accessioned2017-11-20T14:54:52Z
dc.date.available2017-11-20T14:54:52Z
dc.date.issued2017
dc.identifier.citationThe UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010). 2017, 18(Suppl 1): 122 Trialsen
dc.identifier.urihttp://hdl.handle.net/10541/620635
dc.language.isoenen
dc.titleThe UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU)en
dc.identifier.journalTrialsen


This item appears in the following Collection(s)

Show simple item record